Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : U.S. will accept mixed doses of vaccines from international travelers

10/15/2021 | 07:02pm EST

WASHINGTON, Oct 15 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said late on Friday that it will accept mixed-dose coronavirus vaccines from international travelers, a boost to travelers from Canada and other places.

The CDC said last week that https://www.reuters.com/world/us/us-will-accept-who-approved-covid-19-vaccines-international-visitors-2021-10-08 it would accept any vaccine authorized for use by U.S. regulators or the World Health Organization. "While CDC has not recommended mixing types of vaccine in a primary series, we recognize that this is increasingly common in other countries so should be accepted for the interpretation of vaccine records," a CDC spokeswoman said.

The White House said Friday the new vaccine requirements for foreign nationals traveling to the United States will begin Nov. 8 for visitors crossing at land borders as well as international air travelers.

Representative Brian Higgins, a New York Democrat representing a district along the Canadian border, had on Friday asked the CDC if it would accept the mixed vaccine doses noting "nearly four million Canadians, equivalent to 10% of their fully vaccinated population, have received mixed doses of the available mRNA COVID-19 vaccines – this includes the AstraZeneca vaccine."

The CDC said the vaccines approved by the Food and Drug Administration (FDA) for use, as well as those authorized by the WHO, will https://covid19.trackvaccines.org/agency/who be accepted for entry into the United States, including the AstraZeneca vaccine.

The CDC said "individuals who have any combination of two doses of an FDA approved/authorized or WHO emergency use listed COVID-19 two-dose series are considered fully vaccinated."

The CDC plans to answer other questions and release a contact tracing order for international air visitors by Oct. 25. (Reporting by David Shepardson; Editing by Leslie Adler and Aurora Ellis)


ę Reuters 2021
All news about ASTRAZENECA PLC
04:34aWith new Omicron case detected, UK awaits COVID booster advice
RE
11/26ADRs Close Lower; BioNTech Rises, Carnival Drops
DJ
11/26AstraZeneca examining impact of new COVID variant on vaccine, antibody cocktail
RE
11/26AstraZeneca Reportedly Studying New Variant's Impact on Vaccine
MT
11/26AstraZeneca hopeful its antibody cocktail will work on new COVID variant
RE
11/26EU eases its controls on COVID-19 vaccine exports
AQ
11/26India resumes coronavirus vaccine exports to COVAX
RE
11/26India's Serum Institute resumes Covishield vaccine exports under COVAX facility
RE
11/25Clover Bio's COVID Vaccine Candidate to Begin Phase 2 Clinical Trial as Booster Dose
MT
11/25Inaugural Asia Summit on Global Health successfully explores healthcare landscape
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 38,1x
Yield 2021 2,51%
Capitalization 174 B 174 B -
EV / Sales 2021 5,54x
EV / Sales 2022 4,53x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 112,12 $
Average target price 137,74 $
Spread / Average Target 22,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC14.84%173 523
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049